Tripp Levy PLLC Announces Investigation Of Anadys Pharmaceuticals
Tripp Levy PLLC, a leading national securities law firm, announces an investigation into the proposed acquisition of Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS). Anadys announced that it has entered into a definitive merger agreement to be acquired by Roche (SIX: RO, ROG; OTCQX: RHHBY). Under the terms of the merger agreement, Roche will commence an all cash tender offer for all outstanding shares of common stock of Anadys at USD 3.70 per share.
The investigation concerns, among other things, whether the consideration to be paid to ANDS shareholders is unfair, inadequate, and substantially below the fair or inherent value. Indeed, analysts have projected that the true inherent value of PPDI is at least $4 per share. The investigation further concerns whether the board of directors of ANDS may have breached their fiduciary duties by not acting in ANDS shareholders' best interests in connection with the sale process of ANDS. Indeed, each of Anadys' directors and executive officers has agreed to tender their shares in the offer.
If you own ANDS common stock and you wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact
|Tripp Levy PLLC|
|125 East 82 nd Street|
|9 th Floor|
|New York, New York|
|Toll Free: 877-772-3975|
Tripp Levy PLLC is a national law firm that specializes in mergers & acquisitions, takeover litigation, shareholder rights, and corporate governance matters in state and federal courts throughout the United States. Attorney advertising. Prior results do not guarantee a similar outcome.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV